Logo image of AGEN

AGENUS INC (AGEN) Stock Overview

NASDAQ:AGEN - US00847G8042 - Common Stock

4.52 USD
-0.05 (-1.09%)
Last: 8/22/2025, 8:00:00 PM
4.52 USD
0 (0%)
After Hours: 8/22/2025, 8:00:00 PM

AGEN Key Statistics, Chart & Performance

Key Statistics
52 Week High7.34
52 Week Low1.38
Market Cap144.01M
Shares31.86M
Float31.33M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-7.15
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/bmo
IPO02-04 2000-02-04
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


AGEN short term performance overview.The bars show the price performance of AGEN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

AGEN long term performance overview.The bars show the price performance of AGEN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of AGEN is 4.52 USD. In the past month the price decreased by -24.16%. In the past year, price decreased by -22.07%.

AGENUS INC / AGEN Daily stock chart

AGEN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.89 372.04B
AMGN AMGEN INC 13.47 158.13B
GILD GILEAD SCIENCES INC 14.83 142.41B
VRTX VERTEX PHARMACEUTICALS INC 23.32 101.30B
REGN REGENERON PHARMACEUTICALS 12.92 62.48B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.56B
ARGX ARGENX SE - ADR 71.2 40.39B
ONC BEONE MEDICINES LTD-ADR 6.35 37.29B
INSM INSMED INC N/A 27.88B
BNTX BIONTECH SE-ADR N/A 26.66B
NTRA NATERA INC N/A 22.73B
BIIB BIOGEN INC 8.7 20.42B

About AGEN

Company Profile

AGEN logo image Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2000-02-04. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Company Info

AGENUS INC

3 Forbes Rd

Lexington MASSACHUSETTS 02421 US

CEO: Garo H. Armen

Employees: 316

AGEN Company Website

AGEN Investor Relations

Phone: 17816744400

AGENUS INC / AGEN FAQ

What is the stock price of AGENUS INC today?

The current stock price of AGEN is 4.52 USD. The price decreased by -1.09% in the last trading session.


What is the ticker symbol for AGENUS INC stock?

The exchange symbol of AGENUS INC is AGEN and it is listed on the Nasdaq exchange.


On which exchange is AGEN stock listed?

AGEN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AGENUS INC stock?

11 analysts have analysed AGEN and the average price target is 11.22 USD. This implies a price increase of 148.23% is expected in the next year compared to the current price of 4.52. Check the AGENUS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AGENUS INC worth?

AGENUS INC (AGEN) has a market capitalization of 144.01M USD. This makes AGEN a Micro Cap stock.


How many employees does AGENUS INC have?

AGENUS INC (AGEN) currently has 316 employees.


What are the support and resistance levels for AGENUS INC (AGEN) stock?

AGENUS INC (AGEN) has a support level at 4.26 and a resistance level at 4.53. Check the full technical report for a detailed analysis of AGEN support and resistance levels.


Is AGENUS INC (AGEN) expected to grow?

The Revenue of AGENUS INC (AGEN) is expected to grow by 20.33% in the next year. Check the estimates tab for more information on the AGEN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AGENUS INC (AGEN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AGENUS INC (AGEN) stock pay dividends?

AGEN does not pay a dividend.


When does AGENUS INC (AGEN) report earnings?

AGENUS INC (AGEN) will report earnings on 2025-11-10, before the market open.


What is the Price/Earnings (PE) ratio of AGENUS INC (AGEN)?

AGENUS INC (AGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.15).


What is the Short Interest ratio of AGENUS INC (AGEN) stock?

The outstanding short interest for AGENUS INC (AGEN) is 8.03% of its float. Check the ownership tab for more information on the AGEN short interest.


AGEN Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to AGEN. When comparing the yearly performance of all stocks, AGEN is a bad performer in the overall market: 74.41% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AGEN Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to AGEN. AGEN may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AGEN Financial Highlights

Over the last trailing twelve months AGEN reported a non-GAAP Earnings per Share(EPS) of -7.15. The EPS increased by 37.06% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -89.45%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%60.32%
Sales Q2Q%9.28%
EPS 1Y (TTM)37.06%
Revenue 1Y (TTM)-36.29%

AGEN Forecast & Estimates

11 analysts have analysed AGEN and the average price target is 11.22 USD. This implies a price increase of 148.23% is expected in the next year compared to the current price of 4.52.

For the next year, analysts expect an EPS growth of 102.13% and a revenue growth 20.33% for AGEN


Analysts
Analysts76.36
Price Target11.22 (148.23%)
EPS Next Y102.13%
Revenue Next Year20.33%

AGEN Ownership

Ownership
Inst Owners33.72%
Ins Owners1.94%
Short Float %8.03%
Short Ratio2.32